# US 2026/0286321 A1 · Rna replicons, compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0286321 A1
- Document ID: US20260286321A1
- Status: Published application
- Kind: A1
- Application number: 19/684,113
- Filed: 2026-05-21
- Published: 2026-09-24
- Earliest claimed: 2024-03-08
- Assignees: Able Sciences, Inc.
- Applicants: Able Sciences, Inc.
- Inventors: Jolly M. CHENDRIMADA; Thimmaiah CHENDRIMADA
- Web page: https://patentgrep.com/patent/US20260286321A1

## CPC

- C12N 9/127: {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/35: Cytokines
- A61P 11/06: Antiasthmatics
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- C07K 14/5406: {IL-4}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/247: {IL-4}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/85: for animal cells
- C12Y 207/07048: RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- C12N 2820/60: from viruses
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides novel self-amplifying RNA (saRNA) constructs engineered for enhanced protein expression, prolonged durability, reduced immunogenicity, and homogeneous expression of multiple therapeutic proteins. The saRNA constructs comprise a 5′ untranslated region, non-structural protein genes derived from alphaviruses, at least one gene of interest encoding a therapeutic protein, a 3′ untranslated region, and modified nucleosides. Also disclosed are dual construct systems and multivalent polycistronic constructs with flexible, modular component arrangements, including bivalent through hexavalent embodiments encoding combinations of chimeric antigen receptors (CARs), cytokine-anchored chimeric antigen receptors (CCARs), cytokines, cytokine muteins, immune checkpoint inhibitors, and co-stimulatory molecules. Methods of producing and using the saRNA constructs for engineering immune cells for treatment of cancer, inflammatory conditions, and infectious diseases are provided.

## Claims

### Claim 1

A self-amplifying RNA (saRNA) construct comprising a 5′ untranslated region (5′UTR), non-structural protein (NSP) genes encoding an RNA-dependent RNA polymerase complex, at least one subgenomic promoter operably linked to at least one gene of interest encoding a therapeutic protein, and a 3′ untranslated region (3′UTR), wherein the NSP genes comprise one or more modifications to enhance protein expression, increase durability, or reduce immunogenicity.

### Claim 2 (depends on 1)

The saRNA construct of claim 1, wherein the construct is a polycistronic construct encoding at least two therapeutic proteins, wherein the therapeutic proteins are selected from the group consisting of a chimeric antigen receptor (CAR), a cytokine-anchored chimeric antigen receptor (CCAR), a cytokine, and a cytokine mutein.

### Claim 3 (depends on 2)

The saRNA construct of claim 2, wherein the construct is a trivalent construct comprising a first CCAR, a cytokine or cytokine mutein, and a second CCAR, and wherein the arrangement of the first CCAR, the cytokine or cytokine mutein, and the second CCAR is not limited to a fixed order.

### Claim 4 (depends on 1, 2, 3)

An engineered immune cell comprising the saRNA construct of any one of claims 1 to 3.

### Claim 5 (depends on 4)

A method for treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the engineered immune cells of claim 4, wherein the disease is selected from the group consisting of cancer, an eosinophilic disease, an inflammatory condition, and an autoimmune disease.
